Literature DB >> 27750237

Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.

Takayuki Iwamoto, Yasuharu Imai, Sachiyo Kogita, Takumi Igura, Yoshiyuki Sawai, Kazuto Fukuda, Yoshitaka Yamaguchi, Yasushi Matsumoto, Masanori Nakahara, Osakuni Morimoto, Yasushi Seki, Hiroshi Ohashi, Norihiko Fujita, Masatoshi Kudo, Tetsuo Takehara.   

Abstract

OBJECTIVE: We compared the efficacy of contrast-enhanced ultrasound sonography (CEUS) with sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI for the assessment of macroscopic classification of nodular hepatocellular carcinoma (HCC).
METHODS: Seventy-seven consecutive patients with 79 surgically resected HCCs who underwent both preoperative CEUS and Gd-EOB-DTPA-enhanced MRI were enrolled in this retrospective study. Based on the macroscopic diagnosis of resected specimens, nodules were categorized into the simple nodular (SN) and non-SN type HCC. Two hepatologists independently assessed image datasets of the post-vascular phase of CEUS and hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to compare their diagnostic performance.
RESULTS: Gd-EOB-DTPA-enhanced MRI enabled the evaluation of macroscopic classification in a significantly larger number of nodules than CEUS (78/79 (98.7%) vs. 70/79 (88.6%), p < 0.05). Of 70 nodules that could be evaluated by both modalities, 41 and 29 nodules were pathologically categorized as SN and non-SN, respectively. The areas under the receiver operating characteristic curve (AUC) for non-SN did not differ between CEUS and Gd-EOB-DTPA-enhanced MRI (reader 1: 0.748 for CEUS, 0.808 for MRI; reader 2: 0.759 for CEUS, 0.787 for MRI). The AUC of combined CEUS and Gd-EOB-DTPA-enhanced MRI for SN HCC was 0.855 (reader 1) and 0.824 (reader 2), indicating higher AUC values for the combined modalities.
CONCLUSIONS: The diagnostic performance for macroscopic classification of nodular HCC of CEUS was comparable with that of Gd-EOB-DTPA-enhanced MRI, although some HCCs could not be evaluated by CEUS owing to lower detectability. The combination of the 2 modalities had a more accurate diagnostic performance.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27750237     DOI: 10.1159/000448855

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  6 in total

1.  Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.

Authors:  Bao-Min Shi; Wen Lu; Kun Ji; Yu-Feng Wang; Shuai Xiao; Xiu-Yan Wang
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

2.  Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016.

Authors:  Juanjuan Zhang; Yanyan Yu; Ying Li; Lunshou Wei
Journal:  Oncotarget       Date:  2017-08-07

3.  The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.

Authors:  Jiming Wang; Xiaofei Ye; Jiangfa Li; Songqing He
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

4.  Discrepancy of contrast-enhanced ultrasonographic pattern with two contrast agents in steatohepatitic subtype hepatocellular carcinoma: A case report.

Authors:  Jiang Bo; Kong BeiNing; Fei Xiang; Wan XinKun; Luo YuKun
Journal:  Radiol Case Rep       Date:  2022-04-05

5.  Combination of acoustic radiation force impulse imaging, serological indexes and contrast-enhanced ultrasound for diagnosis of liver lesions.

Authors:  Xiao-Lan Sun; Hui Yao; Qiong Men; Ke-Zhu Hou; Zhen Chen; Chang-Qing Xu; Li-Wei Liang
Journal:  World J Gastroenterol       Date:  2017-08-14       Impact factor: 5.742

6.  Significance of contrast-enhanced ultrasonography in differential diagnosis of thyroid nodules.

Authors:  Qing Tian; Haohui Zhu; Hui Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.